|
Market Closed -
Nasdaq
16:00:00 2026-09-21 EDT
|
5-day change | 1st Jan Change | ||
| 153.41 USD | +1.89% |
|
+1.13% | +46.57% |
Company Valuation: Palvella Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| Market Cap 1 | 134.7 | 1,239 | 2,210 | - | - |
| Change | - | 820.07% | 78.41% | - | - |
| Enterprise Value (EV) 1 | 134.7 | 1,181 | 2,020 | 2,210 | 2,210 |
| Change | - | 777.01% | 71.03% | 9.44% | 0% |
| P/E | -1.53x | -28.2x | -23.4x | -18.1x | -24.9x |
| PBR | - | - | - | - | - |
| PEG | - | 0.5x | -0.3x | -0.6x | 0.9x |
| Capitalization / Revenue | - | - | - | 76.6x | 19.4x |
| EV / Revenue | - | - | - | 76.6x | 19.4x |
| EV / EBITDA | -9.55x | -30.6x | -23.5x | -23.6x | -65x |
| EV / EBIT | -9.55x | -30.6x | -21.5x | -16.4x | -22.8x |
| EV / FCF | -12.4x | -32.8x | -25.6x | -22.1x | -27x |
| FCF Yield | -8.05% | -3.05% | -3.91% | -4.52% | -3.7% |
| Dividend per Share 2 | - | - | - | - | - |
| Rate of return | - | - | - | - | - |
| EPS 2 | -7.83 | -3.71 | -6.546 | -8.454 | -6.166 |
| Distribution rate | - | - | - | - | - |
| Net sales 1 | - | - | - | 28.87 | 114 |
| EBITDA 1 | -14.1 | -38.6 | -85.81 | -93.8 | -34.01 |
| EBIT 1 | -14.1 | -38.6 | -93.97 | -134.5 | -96.77 |
| Net income 1 | -17.43 | -41.72 | -94.69 | -136.6 | -102.1 |
| Net Debt 1 | - | -57.98 | -190.6 | - | - |
| Reference price 2 | 12.00 | 104.67 | 153.41 | 153.41 | 153.41 |
| Nbr of stocks (in thousands) | 11,221 | 11,836 | 14,408 | - | - |
| Announcement Date | 3/31/25 | 3/31/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -23.44x | - | -23.54x | - | 2.21B | |
| 21.82x | 7.74x | 15.55x | 1.36% | 74.33B | |
| 32.35x | 9.35x | 29.12x | 0.04% | 62.26B | |
| 32.02x | 6.83x | 17.73x | -.--% | 27.72B | |
| -73.86x | 14.28x | -68.86x | -.--% | 26.42B | |
| -14.99x | 5.59x | -7.02x | -.--% | 24.62B | |
| 28.25x | 5.33x | 17.69x | -.--% | 20.72B | |
| 43.37x | 15.89x | 32.23x | 0.35% | 15.01B | |
| 17.67x | 5.26x | 12.29x | -.--% | 14.18B | |
| -14.6x | 3288.74x | -16.82x | -.--% | 13.48B | |
| Average | 4.86x | 373.22x | 0.84x | 0.19% | 28.1B | |
| Weighted average by Cap. | 12.25x | 167.26x | 7.88x | 0.39% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- PVLA Stock
- Valuation Palvella Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
